Yifan Xinfu Pharmaceutical Co Ltd Total Liabilities
Yifan Xinfu Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Yifan Xinfu Pharmaceutical Co Ltd (002019) has total liabilities worth CN¥4.08 Billion CNY (≈ $597.66 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002019 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Yifan Xinfu Pharmaceutical Co Ltd (2001–2025)
Total liabilities of Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2025. This chart illustrates how Yifan Xinfu Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 002019 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Yifan Xinfu Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Yifan Xinfu Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PG Electroplast Limited
NSE:PGEL
|
India | Rs-30.49 Billion |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
China | CN¥7.18 Billion |
|
SES S.A
F:SES
|
Germany | €7.65 Billion |
|
Thanachart Capital Public Company Limited
BK:TCAP-R
|
Thailand | ฿76.27 Billion |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
USA | $16.70 Billion |
|
Huntsman Corporation
NYSE:HUN
|
USA | $4.23 Billion |
|
Wonik Holdings Co. Ltd
KQ:030530
|
Korea | ₩641.00 Billion |
|
Jinke Property Group Co Ltd
SHE:000656
|
China | CN¥9.73 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Yifan Xinfu Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002019 current and non-current assets.
Liquidity & Leverage Metrics
Yifan Xinfu Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Yifan Xinfu Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yifan Xinfu Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yifan Xinfu Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.13 Billion ≈ $604.94 Million |
+7.13% |
| 2024-12-31 | CN¥3.86 Billion ≈ $564.69 Million |
+18.93% |
| 2023-12-31 | CN¥3.24 Billion ≈ $474.80 Million |
-4.50% |
| 2022-12-31 | CN¥3.40 Billion ≈ $497.15 Million |
+0.20% |
| 2021-12-31 | CN¥3.39 Billion ≈ $496.16 Million |
+13.44% |
| 2020-12-31 | CN¥2.99 Billion ≈ $437.38 Million |
-7.87% |
| 2019-12-31 | CN¥3.24 Billion ≈ $474.71 Million |
+12.36% |
| 2018-12-31 | CN¥2.89 Billion ≈ $422.49 Million |
+45.42% |
| 2017-12-31 | CN¥1.99 Billion ≈ $290.54 Million |
-35.60% |
| 2016-12-31 | CN¥3.08 Billion ≈ $451.13 Million |
+85.03% |
| 2015-12-31 | CN¥1.67 Billion ≈ $243.81 Million |
+110.58% |
| 2014-12-31 | CN¥791.21 Million ≈ $115.78 Million |
+174.54% |
| 2013-12-31 | CN¥288.20 Million ≈ $42.17 Million |
-50.37% |
| 2012-12-31 | CN¥580.73 Million ≈ $84.98 Million |
-16.65% |
| 2011-12-31 | CN¥696.73 Million ≈ $101.95 Million |
+39.97% |
| 2010-12-31 | CN¥497.79 Million ≈ $72.84 Million |
+118.99% |
| 2009-12-31 | CN¥227.31 Million ≈ $33.26 Million |
-20.35% |
| 2008-12-31 | CN¥285.39 Million ≈ $41.76 Million |
-15.03% |
| 2007-12-31 | CN¥335.87 Million ≈ $49.15 Million |
+25.36% |
| 2006-12-31 | CN¥267.92 Million ≈ $39.21 Million |
+36.68% |
| 2005-12-31 | CN¥196.02 Million ≈ $28.68 Million |
+302.32% |
| 2004-12-31 | CN¥48.72 Million ≈ $7.13 Million |
-53.48% |
| 2003-12-31 | CN¥104.73 Million ≈ $15.32 Million |
+99.37% |
| 2002-12-31 | CN¥52.53 Million ≈ $7.69 Million |
+49.85% |
| 2001-12-31 | CN¥35.05 Million ≈ $5.13 Million |
-- |
About Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products, vitamins, and polymer materials in China, South Korea, the Philippines, Vietnam, Italy, Thailand, and internationally. It offers pharmaceutical products, such as biopharmaceuticals, chemical drugs, and traditional Chinese medicines; vitamin products, including vitamin B5 and provi… Read more